Generics BulletinIt’s official: Coherus BioSciences is finally out of the biosimilars business. The company has marked the end of a long road to transition from being a biosimilars player to an innovative immuno-oncol
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
ScripCoherus BioSciences has been transitioning from a focus on biosimilars to developing and commercializing its own immuno-oncology therapies – led by anti-PD-1 agent Loqtorzi (toripalimab-tpzi) – and it
Generics BulletinCoherus BioSciences is out of the biosimilars business. Having in recent years transitioned from its initial specialization in biosimilars to a new focus on innovative immuno-oncology products, the US